Magnetofection

Last updated

Magnetofection is a transfection method that uses magnetic fields to concentrate particles containing vectors to target cells in the body. [1] Magnetofection has been adapted to a variety of vectors, including nucleic acids, non-viral transfection systems, and viruses. This method offers advantages such as high transfection efficiency and biocompatibility which are balanced with limitations.

Contents

Mechanism

Principle

The term magnetofection, currently trademarked by the company OZ Biosciences, combines the words magnetic and transfection. [2] Magnetofection uses nucleic acids associated with magnetic nanoparticles. These molecular complexes are then concentrated and transported into cells using an applied magnetic field.

Synthesis

The magnetic nanoparticles are typically made from iron oxide, which is fully biodegradable, using methods such as coprecipitation or microemulsion. [3] [4]

The nanoparticles are then combined with gene vectors (DNA, siRNA, ODN, virus, etc.). One method involves linking viral particles to magnetic particles using an avidin-biotin interaction. [5] Viruses can also bind to the nanoparticles via hydrophobic interaction. [6]

Another synthesis method involves coating magnetic nanoparticles with cationic lipids or polymers via salt-induced aggregation. For example, nanoparticles may be conjugated with the polyethylenimine (PEI), a positively charged polymer used commonly as a transfection agent. [7] The PEI solution must have a high pH during synthesis to encourage high gene expression. [8] The positively charged nanoparticles can then associate with negatively charged nucleic acids via electrostatic interaction. [9]

The process of magnetofection. Magnet concentrates nanoparticles with gene vectors to cells for transfection. Magnetofection with labels.png
The process of magnetofection. Magnet concentrates nanoparticles with gene vectors to cells for transfection.

Cellular uptake

Magnetic particles loaded with vectors are concentrated on the target cells by the influence of an external magnetic field. The cells then take up genetic material naturally via endocytosis and pinocytosis. Consequently, membrane architecture and structure stays intact, in contrast to other physical transfection methods such as electroporation or gene guns that damage the cell membrane. [10]

The nucleic acids are then released into the cytoplasm by different mechanisms depending upon the formulation used:

  1. the proton sponge effect caused by cationic polymers coated on the nanoparticles that promote endosome osmotic swelling, disruption of the endosome membrane and intracellular release of DNA form,
  2. the destabilization of endosome by cationic lipids coated on the particles that release the nucleic acid into cells by flip-flop of cell negative lipids and charge neutralization and
  3. the viral infection mechanism.

Magnetofection works with cells that are not dividing or slowly dividing, meaning that the genetic materials can go to the cell nucleus without cell division. [11]

Applications

Magnetofection has been tested on a broad range of cell lines, hard-to-transfect and primary cells. [12] Several optimized and efficient magnetic nanoparticle formulations have been specifically developed for several types of applications such as DNA, siRNA, and primary neuron transfection as well as viral applications. [13]

Magnetofection research is currently in the preclinical stage. This technique has primarily been tested in vivo using plasmid DNA in mouse, rat, and rabbit models for applications in the hippocampus, subcutaneous tumors, lungs, spinal cord, and muscle. [14]

Neural stem cells growing in culture. Neural Stem Cells.jpg
Neural stem cells growing in culture.

Some applications include:

Advantages

Magnetofection attempts to unite the advantages of biochemical (cationic lipids or polymers) and physical (electroporation, gene gun) transfection methods. It allows for local delivery with high transfection efficiency, faster incubation time, and biocompatibility. [19]

Transfection efficiency

Coupling magnetic nanoparticles to gene vectors results in hundreds-fold increase of the uptake of these vectors on a time scale of minutes, thus leading to high transfection efficiency. [20] Gene vector and magnetic nanoparticle complexes are transfected into cells after 10–15 minutes, which is faster than the 2–4 hours that other transfection methods require. [21] After 24, 48 or 72 hours, most of the particles are localized in the cytoplasm, in vacuoles (membranes surrounded structure into cells) and occasionally in the cell nucleus. [22]

Biocompatibility

Magnetic nanoparticles do not aggregate easily once the magnet is removed, and therefore are unlikely to block capillaries or cause thrombosis. [23] In addition, iron oxide is biodegradable, and the iron can be reused in hemoglobin or iron metabolism pathways. [24] [25]

Disadvantages

Particle variability

Magnetic nanoparticle synthesis can sometimes lead to a wide range of differently sized particles. [26] The size of particles can influence their usefulness. Specifically, nanoparticles that are less than 10 nm or greater than 200 nm in size tend to be cleared from the body more quickly. [27]

Localization in vivo

While magnets can be used to localize magnetic nanoparticles to desired cells, this mechanism may be difficult to maintain in practice. The nanoparticles can be concentrated in 2D space such as on a culture plate or at the surface of the body, but it can be more difficult to localize them in the 3D space of the body. Magnetofection does not work well for organs or blood vessels far from the surface of the body, since the magnetic field weakens as distance increases. [28] [29] In addition, the user must consider the frequency and timing of applying the magnetic field, as the particles will not necessarily stay in the desired location once the magnet is removed. [30]

Cytotoxicity

While iron oxide used to make nanoparticles is biodegradable, the toxicity of magnetic nanoparticles is still under investigation. Some research has found no signs of damage to cells, while others claim that small (< 2 nm) nanoparticles can diffuse across cell membranes and disrupt organelles. [31] [32]

In addition, very high concentrations of iron oxide can disrupt homeostasis and lead to iron overload, which can damage or alter DNA, affect cellular responses, and kill cells. [33] Lysosymes can also digest the nanoparticles and release free iron which can react with hydrogen peroxide to form free radicals, leading to cytotoxic, mutagenic, and carcinogenic effects. [34]

Related Research Articles

Nanomedicine is the medical application of nanotechnology. Nanomedicine ranges from the medical applications of nanomaterials and biological devices, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology such as biological machines. Current problems for nanomedicine involve understanding the issues related to toxicity and environmental impact of nanoscale materials.

<span class="mw-page-title-main">Small interfering RNA</span> Biomolecule

Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA at first non-coding RNA molecules, typically 20-24 base pairs in length, similar to miRNA, and operating within the RNA interference (RNAi) pathway. It interferes with the expression of specific genes with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation.

Transfection is the process of deliberately introducing naked or purified nucleic acids into eukaryotic cells. It may also refer to other methods and cell types, although other terms are often preferred: "transformation" is typically used to describe non-viral DNA transfer in bacteria and non-animal eukaryotic cells, including plant cells. In animal cells, transfection is the preferred term as transformation is also used to refer to progression to a cancerous state (carcinogenesis) in these cells. Transduction is often used to describe virus-mediated gene transfer into eukaryotic cells.

<span class="mw-page-title-main">Nanochemistry</span> Combination of chemistry and nanoscience

Nanochemistry is an emerging sub-discipline of the chemical and material sciences that deals with the development of new methods for creating nanoscale materials. The term "nanochemistry" was first used by Ozin in 1992 as 'the uses of chemical synthesis to reproducibly afford nanomaterials from the atom "up", contrary to the nanoengineering and nanophysics approach that operates from the bulk "down"'. Nanochemistry focuses on solid-state chemistry that emphasizes synthesis of building blocks that are dependent on size, surface, shape, and defect properties, rather than the actual production of matter. Atomic and molecular properties mainly deal with the degrees of freedom of atoms in the periodic table. However, nanochemistry introduced other degrees of freedom that controls material's behaviors by transformation into solutions. Nanoscale objects exhibit novel material properties, largely as a consequence of their finite small size. Several chemical modifications on nanometer-scaled structures approve size dependent effects.

<span class="mw-page-title-main">Cationic liposome</span>

Cationic liposomes are spherical structures that contain positively charged lipids. Cationic liposomes can vary in size between 40 nm and 500 nm, and they can either have one lipid bilayer (monolamellar) or multiple lipid bilayers (multilamellar). The positive charge of the phospholipids allows cationic liposomes to form complexes with negatively charged nucleic acids through ionic interactions. Upon interacting with nucleic acids, cationic liposomes form clusters of aggregated vesicles. These interactions allow cationic liposomes to condense and encapsulate various therapeutic and diagnostic agents in their aqueous compartment or in their lipid bilayer. These cationic liposome-nucleic acid complexes are also referred to as lipoplexes. Due to the overall positive charge of cationic liposomes, they interact with negatively charged cell membranes more readily than classic liposomes. This positive charge can also create some issues in vivo, such as binding to plasma proteins in the bloodstream, which leads to opsonization. These issues can be reduced by optimizing the physical and chemical properties of cationic liposomes through their lipid composition. Cationic liposomes are increasingly being researched for use as delivery vectors in gene therapy due to their capability to efficiently transfect cells. A common application for cationic liposomes is cancer drug delivery.

Targeted drug delivery, sometimes called smart drug delivery, is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. This means of delivery is largely founded on nanomedicine, which plans to employ nanoparticle-mediated drug delivery in order to combat the downfalls of conventional drug delivery. These nanoparticles would be loaded with drugs and targeted to specific parts of the body where there is solely diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted release system releases the drug in a dosage form. The advantages to the targeted release system is the reduction in the frequency of the dosages taken by the patient, having a more uniform effect of the drug, reduction of drug side-effects, and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult, and the reduced ability to adjust the dosages.

<span class="mw-page-title-main">Gene delivery</span> Introduction of foreign genetic material into host cells

Gene delivery is the process of introducing foreign genetic material, such as DNA or RNA, into host cells. Gene delivery must reach the genome of the host cell to induce gene expression. Successful gene delivery requires the foreign gene delivery to remain stable within the host cell and can either integrate into the genome or replicate independently of it. This requires foreign DNA to be synthesized as part of a vector, which is designed to enter the desired host cell and deliver the transgene to that cell's genome. Vectors utilized as the method for gene delivery can be divided into two categories, recombinant viruses and synthetic vectors.

Magnetic-targeted carriers, also known as MTCs or magnetic vehicles, are micro- or nanoparticles that carry an anticancer drug to the target site by using an external magnetic field and field gradient to direct the desired drug. Usually the complex involves microscopic beads of activated carbon, which bind the anticancer drug. A magnet applied from outside the body then can direct the drug to the tumor site. This can keep a larger dose of the drug at the tumor site for a longer period of time, and help protect healthy tissue from the side effects of chemotherapy.

Magnetic nanoparticles are a class of nanoparticle that can be manipulated using magnetic fields. Such particles commonly consist of two components, a magnetic material, often iron, nickel and cobalt, and a chemical component that has functionality. While nanoparticles are smaller than 1 micrometer in diameter, the larger microbeads are 0.5–500 micrometer in diameter. Magnetic nanoparticle clusters that are composed of a number of individual magnetic nanoparticles are known as magnetic nanobeads with a diameter of 50–200 nanometers. Magnetic nanoparticle clusters are a basis for their further magnetic assembly into magnetic nanochains. The magnetic nanoparticles have been the focus of much research recently because they possess attractive properties which could see potential use in catalysis including nanomaterial-based catalysts, biomedicine and tissue specific targeting, antimicrobial agents, magnetically tunable colloidal photonic crystals, microfluidics, magnetic resonance imaging, magnetic particle imaging, data storage, environmental remediation, nanofluids, optical filters, defect sensor, magnetic cooling and cation sensors.

Magnet-assisted transfection is a transfection method which uses magnetic interactions to deliver DNA into target cells. Nucleic acids are associated with magnetic nanoparticles, and magnetic fields drive the nucleic acid-particle complexes into target cells, where the nucleic acids are released.

Microbubbles (MBs) are bubbles smaller than one hundredth of a millimetre in diameter, but larger than one micrometre. They have widespread application in industry, life science, and medicine. The composition of the bubble shell and filling material determine important design features such as buoyancy, crush strength, thermal conductivity, and acoustic properties.

<span class="mw-page-title-main">Iron oxide nanoparticle</span>

Iron oxide nanoparticles are iron oxide particles with diameters between about 1 and 100 nanometers. The two main forms are magnetite and its oxidized form maghemite. They have attracted extensive interest due to their superparamagnetic properties and their potential applications in many fields.

Biomagnetics is a field of biotechnology. It has actively been researched since at least 2004. Although the majority of structures found in living organisms are diamagnetic, the magnetic field itself, as well as magnetic nanoparticles, microstructures and paramagnetic molecules can influence specific physiological functions of organisms under certain conditions. The effect of magnetic fields on biosystems is a topic of research that falls under the biomagnetic umbrella, as well as the construction of magnetic structures or systems that are either biocompatible, biodegradable or biomimetic. Magnetic nanoparticles and magnetic microparticles are known to interact with certain prokaryotes and certain eukaryotes.

<span class="mw-page-title-main">Vectors in gene therapy</span>

Gene therapy utilizes the delivery of DNA into cells, which can be accomplished by several methods, summarized below. The two major classes of methods are those that use recombinant viruses and those that use naked DNA or DNA complexes.

Gene therapy is being studied for some forms of epilepsy. It relies on viral or non-viral vectors to deliver DNA or RNA to target brain areas where seizures arise, in order to prevent the development of epilepsy or to reduce the frequency and/or severity of seizures. Gene therapy has delivered promising results in early stage clinical trials for other neurological disorders such as Parkinson's disease, raising the hope that it will become a treatment for intractable epilepsy.

Nanoparticles for drug delivery to the brain is a method for transporting drug molecules across the blood–brain barrier (BBB) using nanoparticles. These drugs cross the BBB and deliver pharmaceuticals to the brain for therapeutic treatment of neurological disorders. These disorders include Parkinson's disease, Alzheimer's disease, schizophrenia, depression, and brain tumors. Part of the difficulty in finding cures for these central nervous system (CNS) disorders is that there is yet no truly efficient delivery method for drugs to cross the BBB. Antibiotics, antineoplastic agents, and a variety of CNS-active drugs, especially neuropeptides, are a few examples of molecules that cannot pass the BBB alone. With the aid of nanoparticle delivery systems, however, studies have shown that some drugs can now cross the BBB, and even exhibit lower toxicity and decrease adverse effects throughout the body. Toxicity is an important concept for pharmacology because high toxicity levels in the body could be detrimental to the patient by affecting other organs and disrupting their function. Further, the BBB is not the only physiological barrier for drug delivery to the brain. Other biological factors influence how drugs are transported throughout the body and how they target specific locations for action. Some of these pathophysiological factors include blood flow alterations, edema and increased intracranial pressure, metabolic perturbations, and altered gene expression and protein synthesis. Though there exist many obstacles that make developing a robust delivery system difficult, nanoparticles provide a promising mechanism for drug transport to the CNS.

Magnetoelastic filaments are one-dimensional composite structures that exhibit both magnetic and elastic properties. Interest in these materials tends to focus on the ability to precisely control mechanical events using an external magnetic field. Like piezoelectricity materials, they can be used as actuators, but do not need to be physically connected to a power source. The conformations adopted by magnetoelastic filaments are dictated by the competition between its elastic and magnetic properties.

<span class="mw-page-title-main">Dextran drug delivery systems</span> Polymeric drug carrier

Dextran drug delivery systems involve the use of the natural glucose polymer dextran in applications as a prodrug, nanoparticle, microsphere, micelle, and hydrogel drug carrier in the field of targeted and controlled drug delivery. According to several in vitro and animal research studies, dextran carriers reduce off-site toxicity and improve local drug concentration at the target tissue site. This technology has significant implications as a potential strategy for delivering therapeutics to treat cancer, cardiovascular diseases, pulmonary diseases, bone diseases, liver diseases, colonic diseases, infections, and HIV.

<span class="mw-page-title-main">Intracellular delivery</span> Scientific research area

Intracellular delivery is the process of introducing external materials into living cells. Materials that are delivered into cells include nucleic acids, proteins, peptides, impermeable small molecules, synthetic nanomaterials, organelles, and micron-scale tracers, devices and objects. Such molecules and materials can be used to investigate cellular behavior, engineer cell operations or correct a pathological function.

<span class="mw-page-title-main">Hydrodynamic delivery</span> Gene Transfer Method

Hydrodynamic Delivery (HD) is a method of DNA insertion in rodent models. Genes are delivered via injection into the bloodstream of the animal, and are expressed in the liver. This protocol is helpful to determine gene function, regulate gene expression, and develop pharmaceuticals in vivo.

References

  1. Plank C, Zelphati O, Mykhaylyk O (November 2011). "Magnetically enhanced nucleic acid delivery. Ten years of magnetofection-progress and prospects". Advanced Drug Delivery Reviews. 63 (14–15): 1300–1331. doi:10.1016/j.addr.2011.08.002. PMC   7103316 . PMID   21893135.
  2. "MAGNETOFECTION Trademark of OZ BIOSCIENCES - Registration Number 5116540 - Serial Number 79182650 :: Justia Trademarks". trademarks.justia.com. Retrieved 2021-11-19.
  3. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Lewis BK, Kalish H, Frank JA (December 2003). "Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging". Radiology. 229 (3): 838–846. doi:10.1148/radiol.2293021215. PMID   14657318.
  4. Majidi S, Sehrig FZ, Farkhani SM, Goloujeh MS, Akbarzadeh A (2016-02-17). "Current methods for synthesis of magnetic nanoparticles". Artificial Cells, Nanomedicine, and Biotechnology. 44 (2): 722–734. doi:10.3109/21691401.2014.982802. PMID   25435409. S2CID   31332211.
  5. Mah C, Fraites TJ, Zolotukhin I, Song S, Flotte TR, Dobson J, et al. (July 2002). "Improved method of recombinant AAV2 delivery for systemic targeted gene therapy". Molecular Therapy. 6 (1): 106–112. doi: 10.1006/mthe.2001.0636 . PMID   12095310.
  6. Agopian K, Wei BL, Garcia JV, Gabuzda D (March 2006). "A hydrophobic binding surface on the human immunodeficiency virus type 1 Nef core is critical for association with p21-activated kinase 2". Journal of Virology. 80 (6): 3050–3061. doi:10.1128/jvi.80.6.3050-3061.2006. PMC   1395437 . PMID   16501114.
  7. Cui Y, Li X, Zeljic K, Shan S, Qiu Z, Wang Z (October 2019). "Effect of PEGylated Magnetic PLGA-PEI Nanoparticles on Primary Hippocampal Neurons: Reduced Nanoneurotoxicity and Enhanced Transfection Efficiency with Magnetofection". ACS Applied Materials & Interfaces. 11 (41): 38190–38204. doi:10.1021/acsami.9b15014. PMID   31550131. S2CID   202762218.
  8. Prosen, Lara; Prijic, Sara; Music, Branka; Lavrencak, Jaka; Cemazar, Maja; Sersa, Gregor (2013-06-03). "Magnetofection: A Reproducible Method for Gene Delivery to Melanoma Cells". BioMed Research International. 2013: e209452. doi: 10.1155/2013/209452 . ISSN   2314-6133. PMC   3686069 . PMID   23862136.
  9. Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Krüger A, et al. (January 2002). "Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo". Gene Therapy. 9 (2): 102–109. doi:10.1038/sj.gt.3301624. PMID   11857068. S2CID   1565485.
  10. Fus-Kujawa, Agnieszka; Prus, Pawel; Bajdak-Rusinek, Karolina; Teper, Paulina; Gawron, Katarzyna; Kowalczuk, Agnieszka; Sieron, Aleksander L. (2021-07-20). "An Overview of Methods and Tools for Transfection of Eukaryotic Cells in vitro". Frontiers in Bioengineering and Biotechnology. 9: 701031. doi: 10.3389/fbioe.2021.701031 . ISSN   2296-4185. PMC   8330802 . PMID   34354988.
  11. Fajrial, Apresio K.; He, Qing Qing; Wirusanti, Nurul I.; Slansky, Jill E.; Ding, Xiaoyun (2020). "A review of emerging physical transfection methods for CRISPR/Cas9-mediated gene editing". Theranostics. 10 (12): 5532–5549. doi:10.7150/thno.43465. ISSN   1838-7640. PMC   7196308 . PMID   32373229.
  12. Plank C, Anton M, Rudolph C, Rosenecker J, Krötz F (August 2003). "Enhancing and targeting nucleic acid delivery by magnetic force". Expert Opinion on Biological Therapy. 3 (5): 745–758. doi:10.1517/14712598.3.5.745. PMID   12880375. S2CID   865185.
  13. Plank, Christian; Zelphati, Olivier; Mykhaylyk, Olga (2011-11-01). "Magnetically enhanced nucleic acid delivery. Ten years of magnetofection—Progress and prospects". Advanced Drug Delivery Reviews. Hybrid nanostructures for diagnostics and therapeutics. 63 (14): 1300–1331. doi:10.1016/j.addr.2011.08.002. ISSN   0169-409X. PMC   7103316 . PMID   21893135.
  14. Sizikov AA, Kharlamova MV, Nikitin MP, Nikitin PI, Kolychev EL (April 2021). "Nonviral Locally Injected Magnetic Vectors for In Vivo Gene Delivery: A Review of Studies on Magnetofection". Nanomaterials. 11 (5): 1078. doi: 10.3390/nano11051078 . PMC   8143545 . PMID   33922066.
  15. Pickard, Mark R.; Adams, Christopher F.; Barraud, Perrine; Chari, Divya M. (2015). "Using Magnetic Nanoparticles for Gene Transfer to Neural Stem Cells: Stem Cell Propagation Method Influences Outcomes". Journal of Functional Biomaterials. 6 (2): 259–276. doi: 10.3390/jfb6020259 . PMC   4493511 . PMID   25918990.
  16. Krötz, Florian; Wit, Cor de; Sohn, Hae-Young; Zahler, Stefan; Gloe, Torsten; Pohl, Ulrich; Plank, Christian (2003-05-01). "Magnetofection—A highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo". Molecular Therapy. 7 (5): 700–710. doi: 10.1016/S1525-0016(03)00065-0 . ISSN   1525-0016. PMID   12718913.
  17. Schillinger, Ulrike (2005). "Advances in magnetofection—magnetically guided nucleic acid delivery". Journal of Magnetism and Magnetic Materials. 293 (1): 501–508. Bibcode:2005JMMM..293..501S. doi:10.1016/j.jmmm.2005.01.032. S2CID   122076397 via Elsivier.
  18. Scherer, F.; Anton, M.; Schillinger, U.; Henke, J.; Bergemann, C.; Krüger, A.; Gänsbacher, B.; Plank, C. (2002). "Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo". Gene Therapy. 9 (2): 102–109. doi:10.1038/sj.gt.3301624. ISSN   1476-5462. PMID   11857068. S2CID   1565485.
  19. Plank, Christian; Zelphati, Olivier; Mykhaylyk, Olga (2011). "Magnetically enhanced nucleic acid delivery. Ten years of magnetofection—Progress and prospects". Advanced Drug Delivery Reviews. 63 (14): 1300–1331. doi:10.1016/j.addr.2011.08.002. ISSN   0169-409X. PMC   7103316 . PMID   21893135.
  20. Scherer, F.; Anton, M.; Schillinger, U.; Henke, J.; Bergemann, C.; Krüger, A.; Gänsbacher, B.; Plank, C. (2002). "Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo". Gene Therapy. 9 (2): 102–109. doi:10.1038/sj.gt.3301624. ISSN   1476-5462. PMID   11857068. S2CID   1565485.
  21. Scherer, F.; Anton, M.; Schillinger, U.; Henke, J.; Bergemann, C.; Krüger, A.; Gänsbacher, B.; Plank, C. (2002). "Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo". Gene Therapy. 9 (2): 102–109. doi:10.1038/sj.gt.3301624. ISSN   1476-5462. PMID   11857068. S2CID   1565485.
  22. Santori MI, Gonzalez C, Serrano L, Isalan M (2006-06-27). "Localized transfection with magnetic beads coated with PCR products and other nucleic acids". Nature Protocols. 1 (2): 526–531. doi:10.1038/nprot.2006.74. PMID   17406278. S2CID   23641355.
  23. Wahajuddin; Arora, Sumit (2012). "Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers". International Journal of Nanomedicine. 7: 3445–3471. doi:10.2147/IJN.S30320. ISSN   1176-9114. PMC   3405876 . PMID   22848170.
  24. Castillo, Betzaida; Bromberg, Lev; López, Xaira; Badillo, Valerie; González Feliciano, Jose A.; González, Carlos I.; Hatton, T. Alan; Barletta, Gabriel (2012-08-30). "Intracellular Delivery of siRNA by Polycationic Superparamagnetic Nanoparticles". Journal of Drug Delivery. 2012: e218940. doi: 10.1155/2012/218940 . ISSN   2090-3014. PMC   3437298 . PMID   22970377.
  25. Wahajuddin; Arora, Sumit (2012). "Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers". International Journal of Nanomedicine. 7: 3445–3471. doi:10.2147/IJN.S30320. ISSN   1176-9114. PMC   3405876 . PMID   22848170.
  26. Prosen, Lara; Prijic, Sara; Music, Branka; Lavrencak, Jaka; Cemazar, Maja; Sersa, Gregor (2013-06-03). "Magnetofection: A Reproducible Method for Gene Delivery to Melanoma Cells". BioMed Research International. 2013: e209452. doi: 10.1155/2013/209452 . ISSN   2314-6133. PMC   3686069 . PMID   23862136.
  27. Yetisgin, Abuzer Alp; Cetinel, Sibel; Zuvin, Merve; Kosar, Ali; Kutlu, Ozlem (2020). "Therapeutic Nanoparticles and Their Targeted Delivery Applications". Molecules. 25 (9): 2193. doi: 10.3390/molecules25092193 . PMC   7248934 . PMID   32397080.
  28. Wahajuddin; Arora, Sumit (2012). "Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers". International Journal of Nanomedicine. 7: 3445–3471. doi:10.2147/IJN.S30320. ISSN   1176-9114. PMC   3405876 . PMID   22848170.
  29. Mahmoudi, Morteza; Sant, Shilpa; Wang, Ben; Laurent, Sophie; Sen, Tapas (2011-01-01). "Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy". Advanced Drug Delivery Reviews. 2011 Editors' Collection. 63 (1): 24–46. doi:10.1016/j.addr.2010.05.006. ISSN   0169-409X. PMID   20685224.
  30. Schneider-Futschik, Elena K.; Reyes-Ortega, Felisa (2021). "Advantages and Disadvantages of Using Magnetic Nanoparticles for the Treatment of Complicated Ocular Disorders". Pharmaceutics. 13 (8): 1157. doi: 10.3390/pharmaceutics13081157 . PMC   8400382 . PMID   34452117.
  31. Wei, Hao; Hu (2021). "Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers". International Journal of Nanomedicine. 7: 3445–3471. doi:10.2147/IJN.S30320. ISSN   1178-2013. PMC   3405876 . PMID   22848170.
  32. Wahajuddin; Arora, Sumit (2012-07-06). "Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers". International Journal of Nanomedicine. 7: 3445–3471. doi:10.2147/IJN.S30320. PMC   3405876 . PMID   22848170.
  33. Valdiglesias, Vanessa; Kiliç, Gözde; Costa, Carla; Fernández-Bertólez, Natalia; Pásaro, Eduardo; Teixeira, João Paulo; Laffon, Blanca (2015). "Effects of iron oxide nanoparticles: Cytotoxicity, genotoxicity, developmental toxicity, and neurotoxicity". Environmental and Molecular Mutagenesis. 56 (2): 125–148. doi:10.1002/em.21909. ISSN   1098-2280. PMID   25209650. S2CID   46117152.
  34. Toyokuni, Shinya (1996-01-01). "Iron-induced carcinogenesis: The role of redox regulation". Free Radical Biology and Medicine. 20 (4): 553–566. doi:10.1016/0891-5849(95)02111-6. ISSN   0891-5849. PMID   8904296.

Further reading

See also